MIAMI, Jan. 20, 2016 /PRNewswire/ -- NextSource Biotechnology, LLC announced today that Gleostine® (lomustine) 5 mg
capsules has been approved by the U.S. Food and Drug Administration (FDA) and is now commercially available in the
United States. Gleostine® is approved...
MIAMI, Aug. 7, 2014 /PRNewswire/ -- NextSource Biotechnology (NSB) is a leading specialty pharmaceutical manufacturer with a focus on identifying and developing the most viable
pipeline of "matured" and "innovative drugs" in today's global healthcare market.
The product name change from Lomustine (CCNU)...
MIAMI, Jan. 24, 2014 -- NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company
focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU)...
MIAMI, Sept. 23, 2013 -- NextSource Biotechnology, LLC., (NSB), a leading Specialty Pharmaceutical Manufacturing and Marketing company with
a strategic objective of Consolidating, Re-Branding and launching a "Matured & Orphan Drugs" product portfolio in the U.S. and International Healthcare Markets.